Madrigal Pharmaceuticals (MDGL) Cash & Equivalents (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Cash & Equivalents data on file, last reported at $227.0 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $227.0 million, up 23.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $227.0 million (up 23.63% YoY), and the FY2025 annual result was $198.7 million, up 98.66% from the prior year.
• Cash & Equivalents grew to $227.0 million in Q1 2026 per MDGL's latest filing, from $198.7 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $622.5 million in Q1 2024 and troughed at $42.3 million in Q1 2022.
• A 5-year average of $198.8 million and a median of $183.6 million in 2025 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents surged 814.14% in 2022, then slumped 70.5% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $331.5 million in 2022, then sank by 69.86% to $99.9 million in 2023, then grew by 0.1% to $100.0 million in 2024, then jumped by 98.66% to $198.7 million in 2025, then grew by 14.26% to $227.0 million in 2026.
• Business Quant data shows MDGL's Cash & Equivalents at $227.0 million in Q1 2026, $198.7 million in Q4 2025, and $295.7 million in Q3 2025.